# Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011

> **NCT06235775** · PHASE2 · COMPLETED · sponsor: **GemVax & Kael** · enrollment: 67 (actual)

## Conditions studied

- Progressive Supranuclear Palsy

## Interventions

- **DRUG:** GV1001 Placebo
- **DRUG:** GV1001 1.12mg

## Key facts

- **NCT ID:** NCT06235775
- **Lead sponsor:** GemVax & Kael
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-12
- **Primary completion:** 2025-09-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06235775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06235775, "Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06235775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*